DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Eflapegrastim
Eflapegrastim
ヤンセンファ࣮ч株式会社
Eflapegrastim-Xnst Submitted by Spectrum Pharmaceuticals
WO 2018/102397 Al 07 June 2018 (07.06.2018) W !P O PCT
Drug Utilization R Eview B Oard
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
Korea Innovative PHARMACEUTICAL Company Potential of Pharmaceutical Industry in Korea
(INN) for Biological and Biotechnological Substances
Korea Innovative PHARMACEUTICAL Company Potential of Pharmaceutical Industry in Korea
OCTOBER 2019 Mrx Pipeline a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Rxoutlook® 3Rd Quarter 2020
2019 Biomedtracker Datamonitor Healthcare ASCO Planner
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Optumrx Brand Pipeline Forecast
Rxoutlook® 3Rd Quarter 2021
Optumrx Brand Pipeline Forecast
Brand Pipeline Forecast 4Th Quarter 2019
Isu Abxis • Established in 2000 As a Subsidiary of Isu Chemical Co
INN-Nimet 1 27.11.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
Top View
Annexes to the Annual Report of the European Medicines Agency 2018
Services That Require Precertification Standard Precert Effective: 7/1/2021 This Applies to Elective, Nonemergency Services
2018 Directory of Korean Pharmaceutical Industry
Hanmi Pharmaceutical Progress on R&D, B2B Operations, and Exports
Supplementary Table 1
(INN) for Biological and Biotechnological Substances
SERVICES THAT REQUIRE PRECERTIFICATION Standard Precert Effective: 7/1/2021 This Applies to Elective, Nonemergency Services
January 2018 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2021/0030843 A1 Mohanlal Et Al
Diplomat Specialty Pipeline Report
CTRI Trial Data
Generic Pipeline Forecast This Section Provides a Summary of Upcoming First-Time Generic Drugs and Biosimilars That May Be Approved in the Upcoming Two Years